Any feedback?
Literature summary for 2.4.1.87 extracted from
- A Phase I study of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients with refractory metastatic renal cell carcinoma (2020), Oncologist, 25, 121-e213 .
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | in patients with pretreated metastatic renal cell carcinoma, HyperAcute Renal immunotherapy, i.e. treatment with two allogeneic renal cancer cell lines genetically modified to express alpha(1,3)Gal, is well tolerated and demonstrates antitumor activity | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
